| abstract |
The present disclosure relates to immunoglobulins and immunoglobulin conjugates and compositions with reduced oligomerization and efficient labeling, methods for producing such immunoglobulins and immunoglobulin conjugates, and in particular treatment of diseases and It relates to a method for using such an immunoglobulin conjugate in prevention. In one embodiment, the immunoglobulin conjugate comprises at least one mutation that is a substitution with a cysteine residue, wherein 7 (V H ), 20 (V L ), 22 (V L ), 25 (V H ), 125 An immunoglobulin having a residue selected from the group consisting of (C H1 ), 248 (C H2 ), 254 (C H2 ), 286 (C H2 ), 298 (C H2 ), and 326 (C H2 ); And an atom or molecule conjugated to the cysteine residue. |